119th Congress · introduced in the House · Jun 4, 2026
Prohibiting Adversarial Patents Act of 2026
Official title from Congress.gov
Latest action (Jun 4, 2026): Referred to the House Committee on the Judiciary.
View on Congress.govPolicy area: Commerce
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on the Judiciary.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
11 citations.
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Copyright/Patent/Trademark
$2,560,000
Spent on own lobbying
…-Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Trade (domestic/foreign)
$7,040,000
Spent on own lobbying
…Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff polic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Trade (domestic/foreign)
$1,530,000
Spent on own lobbying
…Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff polic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ITC MODERNIZATION ALLIANCE · lobbying firm or registrant: FRANKLIN SQUARE GROUP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Copyright/Patent/Trademark
$50,000
Paid to lobbying firm
…priations related to reforms on the way the International Trade Commission handles patent cases and encouraging transparency in third party litigation funding; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 7015, Protecting TPLF From Abuse Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HIGH TECH INVENTORS ALLIANCE · lobbying firm or registrant: FRANKLIN SQUARE GROUP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Copyright/Patent/Trademark
$70,000
Paid to lobbying firm
…y Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecti…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HIGH TECH INVENTORS ALLIANCE · lobbying firm or registrant: DAVID W JONES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 17, 2026 · issue area: Copyright/Patent/Trademark
$110,000
Paid to lobbying firm
…H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOTECHNOLOGY INNOVATION ORGANIZATION · lobbying firm or registrant: BIOTECHNOLOGY INNOVATION ORGANIZATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Copyright/Patent/Trademark
$2,360,000
Spent on own lobbying
…-Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Trade (domestic/foreign)
$7,360,000
Spent on own lobbying
…on Act for FY 2026) H.R. 4780: USTRx Act H.R. 6089: Biomanufacturing Excellence Act of 2025 H.R. 9102: Biotech Investment National Security Act of 2026 (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff polic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ITC MODERNIZATION ALLIANCE · lobbying firm or registrant: FRANKLIN SQUARE GROUP, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Copyright/Patent/Trademark
$60,000
Paid to lobbying firm
…priations related to reforms on the way the International Trade Commission handles patent cases and encouraging transparency in third party litigation funding; H.R. 9142, Prohibiting Adversarial Patents Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HIGH TECH INVENTORS ALLIANCE · lobbying firm or registrant: FRANKLIN SQUARE GROUP, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Copyright/Patent/Trademark
$70,000
Paid to lobbying firm
…y Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecti…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Trade (domestic/foreign)
$890,000
Spent on own lobbying
…BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff polic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing